LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

Search

Biogen Inc

Avatud

SektorTervishoid

137.21 -0.15

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

135.28

Max

137.65

Põhinäitajad

By Trading Economics

Sissetulek

394M

635M

Müük

215M

2.6B

P/E

Sektori keskmine

13.46

35.69

Aktsiakasum

3.02

Kasumimarginaal

23.995

Töötajad

7,605

EBITDA

457M

1B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+21.72% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. okt 2025

Turustatistika

By TradingEconomics

Turukapital

1.9B

21B

Eelmine avamishind

137.36

Eelmine sulgemishind

137.21

Uudiste sentiment

By Acuity

50%

50%

131 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Biogen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. sept 2025, 18:25 UTC

Suurimad hinnamuutused turgudel

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28. sept 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28. sept 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28. sept 2025, 23:45 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28. sept 2025, 23:34 UTC

Market Talk

Oil Falls on Likely Technical Correction -- Market Talk

27. sept 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26. sept 2025, 20:54 UTC

Tulu

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26. sept 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. sept 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. sept 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26. sept 2025, 19:53 UTC

Omandamised, ülevõtmised, äriostud

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. sept 2025, 19:40 UTC

Tulu

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26. sept 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26. sept 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26. sept 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26. sept 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26. sept 2025, 18:50 UTC

Market Talk
Tulu

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26. sept 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: Global Development Hasn't Received All Necessary Approvals >ING

26. sept 2025, 18:02 UTC

Omandamised, ülevõtmised, äriostud

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26. sept 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26. sept 2025, 16:56 UTC

Market Talk
Tulu

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26. sept 2025, 16:41 UTC

Market Talk
Tulu

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26. sept 2025, 16:26 UTC

Tulu

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26. sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

21.72% tõus

12 kuu keskmine prognoos

Keskmine 167.2 USD  21.72%

Kõrge 224 USD

Madal 118 USD

Põhineb 26 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

26 ratings

12

Osta

14

Hoia

0

Müü

Tehniline skoor

By Trading Central

118.15 / 121.17Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

131 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat